Ines Vasconcelos
Charité Medical University of Berlin, Germany
Title: Borderline ovarian tumors (BOTs)
Biography
Biography: Ines Vasconcelos
Abstract
Borderline ovarian tumors (BOTs) were first described by Taylor in 1929 and have been a challenge for both pathologists and oncologists. BOT is a disease of younger, fertile women, generally with a benign course; however, a minority of patients progress and eventually succumb to the disease. Although the corrected survival for patients with disease confined to the ovary is 100% at 15 years, 30% of patients with serous BOT with invasive implants will develop persistent or recurrent tumor, most commonly low-grade ovarian serous carcinoma. For the group of patients with invasive implants, there is no consensus regarding standard therapy. At present, chemotherapy is offered mostly to patients with invasive implants, regardless of histological subtype. However, response to these agents remains suboptimal with recurrence estimates for patients for patients with BOT with invasive implants undergoing adjuvant treatment remaining high at 44.0%. In this presentation we will discuss the current evidence, or lack of thereof, to support the use of adjuvant treatment in patients with invasive implants in the primary treatment setting.
Speaker Presentations
Speaker PPTs Click Here